The dopa-carboxylase inhibitor carbidopa, in combination with L-Dopa (levodopa), (Sinemet R) has the advantage of achieving a rapid therapeutic response in relatively low doses (one tablet 3 times a day). It has now virtually replaced L-Dopa (levodopa) alone as a form of therapy.